InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
NCT ID: NCT01026285
Last Updated: 2013-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1085 participants
OBSERVATIONAL
2009-06-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
NCT00246194
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
NCT00216632
Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
NCT05480046
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
NCT00774085
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
NCT00558298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
antipsychotic treatment
Risperidone Long-Acting injectable or oral antipsychotics According to label
Risperidone Long-Acting injectable or oral antipsychotics
According to label
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risperidone Long-Acting injectable or oral antipsychotics
According to label
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly initiated on or switched to RLAI or an oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
* Signed informed consent (either signed by the patient or his/her legal representative) is available at the beginning of documentation
* any schizophrenic patient (including those for whom a legal representative must sign consent) can be involved in the study
Exclusion Criteria
* History of neuroleptic malignant syndrome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag International NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen-Cilag International NV Clinical Trial
Role: STUDY_DIRECTOR
Janssen-Cilag International NV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brno, , Czechia
České Budějovice, , Czechia
Most, , Czechia
Olomouc, , Czechia
Prague, , Czechia
Přerov, , Czechia
Bar-le-Duc, , France
Boulogne-Billancourt, , France
Bourg-en-Bresse, , France
Challans, , France
Créteil, , France
Dax, , France
La Roche-sur-Yon, , France
La Seyne-sur-Mer, , France
Laxou, , France
Marseille, , France
Mont-Saint-Martin, , France
Montpellier, , France
Morlaix, , France
Plouguernével, , France
Rennes, , France
Saint-Avé, , France
Saint-Égrève, , France
Sarreguemines, , France
Verdun, , France
Villejuif, , France
Augsburg, , Germany
Bad Honnef, , Germany
Berlin, , Germany
Bochum, , Germany
Butzbach, , Germany
Chemnitz, , Germany
Coesfeld, , Germany
Cologne, , Germany
Dortmund, , Germany
Dresden, , Germany
Düsseldorf, , Germany
Ebensfeld, , Germany
Frankfurt, , Germany
Fürth, , Germany
Geithain, , Germany
Greifswald, , Germany
Grevenbroich, , Germany
Hamburg, , Germany
Ilmenau, , Germany
Köthen, , Germany
Krefeld, , Germany
Leipzig, , Germany
Limburg, , Germany
Löhne, , Germany
Magdeburg, , Germany
Mannheim, , Germany
München, , Germany
Neuss, , Germany
Oranienburg, , Germany
Plauen, , Germany
Potsdam, , Germany
Riesa, , Germany
Schleswig, , Germany
Stolberg, , Germany
Stralsund, , Germany
Ulm, , Germany
Velbert, , Germany
Wetzlar, , Germany
Wismar, , Germany
Wuppertal, , Germany
Arta, , Greece
Athens, , Greece
Chania, , Greece
Crete, , Greece
Ioannina, , Greece
Larissa, , Greece
Thessalonikis, , Greece
Véroia, , Greece
Kronshtadt, , Russia
Nizhny Novgorod, , Russia
Saint Petersburg, , Russia
Yekaterinburg, , Russia
Birmingham, AL, South Africa
Pretoria, , South Africa
A Coruña, , Spain
Burgos, , Spain
Getafe, , Spain
Madrid, , Spain
Monforte de Lemos, , Spain
Salamanca, , Spain
Valladolid, , Spain
Vigo, , Spain
Adana, , Turkey (Türkiye)
Ankara, , Turkey (Türkiye)
Erzurum, , Turkey (Türkiye)
Eskişehir, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Izmir, , Turkey (Türkiye)
Kocaeli, , Turkey (Türkiye)
Manisa, , Turkey (Türkiye)
Mersin, , Turkey (Türkiye)
Trabzon, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
InORS - International Observational Registry on Schizophrenia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RISSCH4230
Identifier Type: OTHER
Identifier Source: secondary_id
CR016630
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.